Cap Flashcards
Pneumonia classified by site of acquisition
D
Pneumonia classified by etiology
D
An acute infection of the pulmonary parenchyma acquired outside of
health care settings
O
An acute infection of the pulmonary parenchyma acquired in hospital
settings, which encompasses hospital-acquired pneumonia and ventilator-associated pneumonia
I
Pneumonia acquired ≥48 hours after hospital admission; includes pneumonia (HAP) both HAP and VAP
K
Pneumonia acquired ≥48 hours after endotracheal intubation
E
Retired term, which referred to pneumonia acquired in health care
facilities (eg, nursing homes, hemodialysis centers) or after recent hospitalization*
S
Pneumonia caused by “atypical” bacterial pathogens including ¶
Legionella spp, Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia psittaci, and Coxiella burnetii
S
Pneumonia resulting from entry of gastric or oropharyngeal fluid,
which may contain bacteria and/or be of low pH, or exogenous substances (eg, ingested food particles or liquids, mineral oil, salt or fresh water) into the lower airways
E
Aspiration of substances (eg, acidic gastric fluid) that cause an
inflammatory reaction in the lower airways, independent of bacterial infection
E
An active infection caused by inoculation of large amounts of bacteria
into the lungs via orogastric contents
I
The most common pathogen in
Medical word
ICU
D
Determine the appropriate site of treatment in adults
D
Septic shock require vasopresser
D
Respiratory failure require mechanical ventilation
D
CURB 65 score 0
S
CURB 65 score 1 or 2
S
CURB 65 score 3 to 5
D
PSI class 1 or 2
D
PSI class 3
D
PSI class IV or V
D
Feature that support ICU level care when patient have 3 and more
D
Altered mental status
S
Hypotension require fluid support
D
Temperature <36 C
S
Respiratory rate 30 and more
S
PaO2/FiO2 ratio < 250
S
Blood urea nitrogen >20 mg /dL
D
Leaukocyte count <4000
F
Platelets count <100,000
E
Multilobar infiltrate
D
Test needed for moderate risk
D
Test needed for sever risk
D
Blood culture
D
Sputum gram stain and culture
D
Urien streptococcus antigen
D
Legionella testing
D
Respiratory viral panel during season
S
COVID 19
S
HIV screening
D
Bronchoscopy
D
Age >65 years
S
Start within 4 hour
D
Start within 1 hour
D
Risk factor for MRSA
D
Risk factor for pseudomonas
D
Known colonization
S
Prior infection with MRSA
S
Gram positive cocci in cluster
D
Receipt of Iv antibiotic during hospitalization in the prior 3 month
D
Recent influza
S
Necrotizing or cavitary pneumonia
D
Presence of emphysema
K
End stage renal disease
D
Living in crowded
D
Contact sport participation
D
Gram negative bacilli
D
Prior infection with pseudomonas
D
Structural lung abnormalities
D
Frequent copd exacerbated require corticosteroids or antibiotic
D
Ant MRSA
D
Aminoglycoside
D
Respiratory fluoroquinolone
D
Anti pseudomonas fluoroquinolone
D
Anti pseudomonas/anti pneumococcal beta lactam
S
Anti pneumococcal beta lactam
S
Macrolide
D
Vancomycin
D
Linezolid
D
Gentamicin
D
Tobramycin
D
Amikacin
S
Levofloxacin
D
Moxifloxacin
D
Gemifloxacin
D
Ciprofloxacin
D
Piperacillin tazobactam
D
Cefepime
D
Ceftazidime
S
Impenem
D
Meropenem
D
Ceftrixone
D
Cefotaxime
S
Ceftaroline
D
Ertapenem
D
Ampicllin sulbactam
S
Azithromycin
S
Clarithromycin
S
Does the patient have a sever beta lactam allergy
MRSA and pseudomonas risk factor
D
Pseudomonas risk factor only
G
MRSA risk factor
F
No MRSA or pseudomonas
D
Anti pneumococcal beta lactam + doxycycline
D
Anti pneumococcal beta lactam + Macrolide
D
Anti pneumococcal beta lactam + doxycycline + anti MRSA
D
Anti pneumococcal beta lactam + doxycycline + anti MRSA
D
Anti MRSA + respiratory fluoroquinolone
S
Levofloxacin + aztreonam + Aminoglycoside
D
Levofloxacin + aztreonam + Aminoglycoside + anti MRSA
S
Respiratory fluoroquinolone + aztreonam
K
Anti MRSA + respiratory fluoroquinolone + aztreonam
D
Transitioning inpatient with CAP from Iv to oral antibiotic
E
Criteria met for change to oral
D
Improve clinically
D
Hemodynamics stable
D
Able to take oral
D
Improve in feve , respiratory StAtus, and white blood count
D
Initial treatment with Iv fluoroquinolone
F
Initial treatment with ceftrixone or cefotaxime + macrolide
F
Switch to oral respiratory fluoroquinolone
E
Amoxicillin
Amoxicillin clavulante
Third generation cephalosporin ( cefpodoxime)
+
Azithromycin
Clarithromycin
Doxycycline
D
Avoid in patient with qt interval prolongation
D
Has similar covers to ceftrixone and cefotaxime
D
If patient has received 1.5 g azithromycin, …..
S
Duration of antibiotic of cap for inpatient
D
Minimal 7 days
D
Longer courses >4 weeks and more
D
Individualized duration
K
A febrile for 48 to 72 hr
D
Supplement oxygen not needed
W
Heart rate >100
S
Respiratory rate >24
D
Systolic blood pressure 90 and less
Discontinue antibiotic after 5 to 7 days
D
Continue antibiotic until stable
Reevaluate at 7 days
D
Recommended drug for streptococcus pneumonia
D
Recommended drug for haemophilus infleunza
C
Penicillin non resistant
D
Penicillin resistant
E
Non beta lactamase producing
F
Beta lactamase production
F
Pencil in G
C
Amoxicillin
D
Cefotaxime
D
Ceftrixone
C
Second or third generation cephalosporin
D
Amoxicillin clavulnate
S
Vancomycin
D
Linezolid
D
High dose amoxicillin
D
Clarithromycin
E
Azithromycin
S
Cefazolin
S
Cefadroxil
D
Cephalexin
D
Cephalothin
C
Cephapirin
F
Cephradine
Cefuroxime
D
Cefoxitin
D
Cefotetan
S
Cefaclor
F
Cefprozil
D
Cefepime
S
Cefpirome
D
Ceftaroline
D
Ceftobiprole
D
Ceftrixone
D
Ceftibuten
F
Cefotaxime
D
Ceftazidime
D
Cefpodoxime
D
Cefixime
D